Skip to main content
Erschienen in: MMW - Fortschritte der Medizin 1/2018

26.03.2018 | Herpesviren | FORTBILDUNG . ÜBERSICHT

Gefährliche Virusinfektion

Herpes zoster — was Sie als Hausarzt wissen müssen

verfasst von: Prof. Dr. med. Uwe Wollina, MD

Erschienen in: MMW - Fortschritte der Medizin | Sonderheft 1/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Gürtelrose manifestiert sich keinesfalls nur im Gürtelbereich. Schwere Verläufe mit Beteiligung der Augen, der Ohren, der Schleimhäute und sogar innerer Organe kommen vor. Zur Vermeidung der häufigsten Komplikation, der postzosterischen Neuralgie, sind eine rasche Diagnose und eine effiziente Therapie nötig. Hier sind Sie als Hausarzt gefragt.
Literatur
1.
Zurück zum Zitat Jensen NJ, Rivailler P, Tseng HF, Quinlivan ML et al. Revisiting the genotyping scheme for varicella-zoster viruses based on whole-genome comparisons. J Gen Virol. 2017;98:1434–8CrossRef Jensen NJ, Rivailler P, Tseng HF, Quinlivan ML et al. Revisiting the genotyping scheme for varicella-zoster viruses based on whole-genome comparisons. J Gen Virol. 2017;98:1434–8CrossRef
2.
Zurück zum Zitat Weinberg A, Canniff J, Rouphael N, Mehta A et al. Varicella-zoster virus-specific cellular immune responses to the live attenuated zoster vaccine in young and older adults. J Immunol. 2017;199:604–12CrossRef Weinberg A, Canniff J, Rouphael N, Mehta A et al. Varicella-zoster virus-specific cellular immune responses to the live attenuated zoster vaccine in young and older adults. J Immunol. 2017;199:604–12CrossRef
3.
Zurück zum Zitat Kurapati S, Sadaoka T, Rajbhandari L, Jagdish B et al. Role of the JNK pathway in varicella-zoster virus lytic infection and reactivation. J Virol. 2017;91: pii: e00640–17CrossRef Kurapati S, Sadaoka T, Rajbhandari L, Jagdish B et al. Role of the JNK pathway in varicella-zoster virus lytic infection and reactivation. J Virol. 2017;91: pii: e00640–17CrossRef
4.
Zurück zum Zitat Silva JR, Lopes AH, Talbot J, Cecilio NT et al. Neuroimmune-glia interactions in the sensory ganglia account for the development of acute herpetic neuralgia. J Neurosci. 2017;37:6408–22CrossRef Silva JR, Lopes AH, Talbot J, Cecilio NT et al. Neuroimmune-glia interactions in the sensory ganglia account for the development of acute herpetic neuralgia. J Neurosci. 2017;37:6408–22CrossRef
5.
Zurück zum Zitat Wiese-Posselt M, Siedler A, Mankertz A, Sauerbrei A et al. Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany. BMC Infect Dis. 2017;17:356CrossRef Wiese-Posselt M, Siedler A, Mankertz A, Sauerbrei A et al. Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany. BMC Infect Dis. 2017;17:356CrossRef
6.
Zurück zum Zitat Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81:928–30CrossRef Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81:928–30CrossRef
7.
Zurück zum Zitat Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170CrossRef Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170CrossRef
8.
Zurück zum Zitat Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect. 2015;70:178–86CrossRef Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect. 2015;70:178–86CrossRef
9.
Zurück zum Zitat Hansson E, Forbes HJ, Langan SM, Smeeth L, Bhaskaran K. Herpes zoster risk after 21 specific cancers: population-based case-control study. Br J Cancer. 2017;116:1643–51CrossRef Hansson E, Forbes HJ, Langan SM, Smeeth L, Bhaskaran K. Herpes zoster risk after 21 specific cancers: population-based case-control study. Br J Cancer. 2017;116:1643–51CrossRef
10.
Zurück zum Zitat Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L et al. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111:1806–15CrossRef Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L et al. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111:1806–15CrossRef
11.
Zurück zum Zitat Winthrop KL, Yamanaka H, Valdez H, Mortensen E et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–84CrossRef Winthrop KL, Yamanaka H, Valdez H, Mortensen E et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–84CrossRef
12.
Zurück zum Zitat Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol. 2014;28:846–52CrossRef Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol. 2014;28:846–52CrossRef
13.
Zurück zum Zitat Schink T, Behr S, Thöne K, Bricout H, Garbe E. Risk of stroke after herpes zoster - evidence from a German self-controlled case-series study. PLoS One. 2016;11:e0166554CrossRef Schink T, Behr S, Thöne K, Bricout H, Garbe E. Risk of stroke after herpes zoster - evidence from a German self-controlled case-series study. PLoS One. 2016;11:e0166554CrossRef
14.
Zurück zum Zitat Marra F, Ruckenstein J, Richardson K. A meta-analysis of stroke risk following herpes zoster infection. BMC Infect Dis. 2017;17:198.CrossRef Marra F, Ruckenstein J, Richardson K. A meta-analysis of stroke risk following herpes zoster infection. BMC Infect Dis. 2017;17:198.CrossRef
15.
Zurück zum Zitat Wollina U, Machetanz J. Herpes zoster and postzosterische Neuralgie. Hautarzt. 2016;67:653–65CrossRef Wollina U, Machetanz J. Herpes zoster and postzosterische Neuralgie. Hautarzt. 2016;67:653–65CrossRef
16.
Zurück zum Zitat Wilson DA, Yen-Lieberman B, Schindler S, Asamoto K et al. Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review. J Clin Microbiol. 2012;50:4120–2CrossRef Wilson DA, Yen-Lieberman B, Schindler S, Asamoto K et al. Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review. J Clin Microbiol. 2012;50:4120–2CrossRef
18.
Zurück zum Zitat Arruti M, Piñeiro LD, Salicio Y, Cilla G et al. Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007–2014). J Neurovirol. 2017;23:451–9CrossRef Arruti M, Piñeiro LD, Salicio Y, Cilla G et al. Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007–2014). J Neurovirol. 2017;23:451–9CrossRef
19.
Zurück zum Zitat Werner RN, Nikkels AF, Marinović B, Schäfer M et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. J Eur Acad Dermatol Venereol. 2017;31:9–19CrossRef Werner RN, Nikkels AF, Marinović B, Schäfer M et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. J Eur Acad Dermatol Venereol. 2017;31:9–19CrossRef
20.
Zurück zum Zitat Ultsch B, Siedler A, Rieck T, Reinhold T et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173CrossRef Ultsch B, Siedler A, Rieck T, Reinhold T et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173CrossRef
21.
Zurück zum Zitat Werner RN, Nikkels AF, Marinović B, Schäfer M et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster — guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol. 2017;31:20–9CrossRef Werner RN, Nikkels AF, Marinović B, Schäfer M et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster — guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol. 2017;31:20–9CrossRef
22.
Zurück zum Zitat Wollina U. Herpes zoster. In: Katsambas A, Lotti T, Dessinioti C, D’Erme AM (Eds). European Handbook of Dermatological Treatments. 3rd Edition. Springer: Berlin Heidelberg 2015: pp. 379–84 Wollina U. Herpes zoster. In: Katsambas A, Lotti T, Dessinioti C, D’Erme AM (Eds). European Handbook of Dermatological Treatments. 3rd Edition. Springer: Berlin Heidelberg 2015: pp. 379–84
23.
Zurück zum Zitat Weaver BA, Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (2011) Update on the advisory committee on immunization practices’ recommendations for use of herpes zoster vaccine. J Am Osteopath Assoc 2011;111(Suppl 6): S31–S33PubMed Weaver BA, Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (2011) Update on the advisory committee on immunization practices’ recommendations for use of herpes zoster vaccine. J Am Osteopath Assoc 2011;111(Suppl 6): S31–S33PubMed
24.
Zurück zum Zitat Le P, Sabella C, Rothberg MB. Preventing herpes zoster through vaccination: New developments. Cleve Clin J Med. 2017;84:359–66CrossRef Le P, Sabella C, Rothberg MB. Preventing herpes zoster through vaccination: New developments. Cleve Clin J Med. 2017;84:359–66CrossRef
25.
Zurück zum Zitat Lal H, Cunningham AL, Godeaux O et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New Engl J Med. 2015;372:2087–96CrossRef Lal H, Cunningham AL, Godeaux O et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New Engl J Med. 2015;372:2087–96CrossRef
26.
Zurück zum Zitat Cunningham AL, Lal H, Kovac M et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New Engl J Med. 2016;375:1019–32CrossRef Cunningham AL, Lal H, Kovac M et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New Engl J Med. 2016;375:1019–32CrossRef
27.
Zurück zum Zitat Blank PR, Ademi Z, Lu X, Szucs TD, Schwenkglenks M. Herpes zoster vaccine: A health economic evaluation for Switzerland. Hum Vaccin Immunother. 2017;13:1495–1504CrossRef Blank PR, Ademi Z, Lu X, Szucs TD, Schwenkglenks M. Herpes zoster vaccine: A health economic evaluation for Switzerland. Hum Vaccin Immunother. 2017;13:1495–1504CrossRef
28.
Zurück zum Zitat Hoshi SL, Kondo M, Okubo I. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Vaccine. 2017;35:3264–71CrossRef Hoshi SL, Kondo M, Okubo I. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Vaccine. 2017;35:3264–71CrossRef
29.
Zurück zum Zitat Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies — update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015;94:1441–50CrossRef Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies — update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015;94:1441–50CrossRef
30.
Zurück zum Zitat Schröder C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Infect. 2017;75:207–15CrossRef Schröder C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Infect. 2017;75:207–15CrossRef
31.
Zurück zum Zitat Lin HC, Chao YH, Wu KH, Yen TY et al. Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study. Medicine (Baltimore). 2016;95:e4037CrossRef Lin HC, Chao YH, Wu KH, Yen TY et al. Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study. Medicine (Baltimore). 2016;95:e4037CrossRef
32.
Zurück zum Zitat Tsai SY, Chen HJ, Lio CF, Ho HP et al. Increased risk of herpes zoster in patients with psoriasis: A population-based retrospective cohort study. PLoS One. 2017;12: e0179447CrossRef Tsai SY, Chen HJ, Lio CF, Ho HP et al. Increased risk of herpes zoster in patients with psoriasis: A population-based retrospective cohort study. PLoS One. 2017;12: e0179447CrossRef
33.
Zurück zum Zitat Ludvigsson JF, Choung RS, Marietta EV, Murray JA, Emilsson L. Increased risk of herpes zoster in patients with coeliac disease — nationwide cohort study. Scand J Public Health. 2017;1403494817714713. doi: 10.1177/1403494817714713. [Epub ahead of print] Ludvigsson JF, Choung RS, Marietta EV, Murray JA, Emilsson L. Increased risk of herpes zoster in patients with coeliac disease — nationwide cohort study. Scand J Public Health. 2017;1403494817714713. doi: 10.1177/1403494817714713. [Epub ahead of print]
34.
Zurück zum Zitat Liao TL, Chen YM, Liu HJ, Chen DY. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open. 2017;7:e014032CrossRef Liao TL, Chen YM, Liu HJ, Chen DY. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open. 2017;7:e014032CrossRef
35.
36.
Zurück zum Zitat Schmidt SA, Mor A, Schønheyder HC, Sørensen HT et al. Herpes zoster as a marker of occult cancer: A systematic review and meta-analysis. J Infect. 2017;74:215–35CrossRef Schmidt SA, Mor A, Schønheyder HC, Sørensen HT et al. Herpes zoster as a marker of occult cancer: A systematic review and meta-analysis. J Infect. 2017;74:215–35CrossRef
37.
Zurück zum Zitat Lai SW, Lin CH, Lin HF, Lin CL et al. Herpes zoster correlates with increased risk of Parkinson’s disease in older people: A population-based cohort study in Taiwan. Medicine (Baltimore). 2017;96:e6075CrossRef Lai SW, Lin CH, Lin HF, Lin CL et al. Herpes zoster correlates with increased risk of Parkinson’s disease in older people: A population-based cohort study in Taiwan. Medicine (Baltimore). 2017;96:e6075CrossRef
38.
Zurück zum Zitat Lin TY, Yang FC, Lin CL, Kao CH et al. Herpes zoster infection increases the risk of peripheral arterial disease: A nationwide cohort study. Medicine (Baltimore). 2016;95:e4480CrossRef Lin TY, Yang FC, Lin CL, Kao CH et al. Herpes zoster infection increases the risk of peripheral arterial disease: A nationwide cohort study. Medicine (Baltimore). 2016;95:e4480CrossRef
39.
Zurück zum Zitat England BR, Mikuls TR, Xie F, Yang S et al. Herpes zoster as a risk factor for incident giant cell arteritis. Arthritis Rheumatol. 2017; doi: 10.1002/art.40236. [Epub ahead of print]CrossRef England BR, Mikuls TR, Xie F, Yang S et al. Herpes zoster as a risk factor for incident giant cell arteritis. Arthritis Rheumatol. 2017; doi: 10.1002/art.40236. [Epub ahead of print]CrossRef
Metadaten
Titel
Gefährliche Virusinfektion
Herpes zoster — was Sie als Hausarzt wissen müssen
verfasst von
Prof. Dr. med. Uwe Wollina, MD
Publikationsdatum
26.03.2018
Verlag
Springer Medizin
Erschienen in
MMW - Fortschritte der Medizin / Ausgabe Sonderheft 1/2018
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI
https://doi.org/10.1007/s15006-018-0006-2

Weitere Artikel der Sonderheft 1/2018

MMW - Fortschritte der Medizin 1/2018 Zur Ausgabe

FORTBILDUNG . KRITISCH GELESEN

Die lange Suche nach den roten Stäbchen

AKTUELLE MEDIZIN . KONGRESSBERICHTE

Abklärung von Synkopen: So gehen Sie vor

AUS DER PRAXIS . VON HAUSARZT ZU HAUSARZT

Abrechnungs-Ausschlüsse unter der Lupe